Home / Market News / $DSNKY

$DSNKY news and market catalysts

The 6 most recent market catalysts affecting $DSNKY, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

6 catalysts 2 high impact 4 bullish 2 bearish Pharmaceuticals
Nov 9, 2026 Corporate Catalyst Bullish Impact 55
Daiichi Sankyo Enters Research Collaboration with iDEL Therapeutics
Daiichi Sankyo announced a multi-year research collaboration with iDEL Therapeutics to explore multi-drug conjugates (MDCs) for solid tumor indications. This partnership is signifi…
Oct 31, 2026 Corporate Catalyst Bullish Impact 85
Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results
Daiichi Sankyo announced strong financial results for Q2 FY26, largely due to the impressive performance of its oncology drugs, Enhertu and Datroway. This is a significant positive…
Aug 17, 2026 Corporate Catalyst Bullish Impact 75
Daiichi Sankyo And AstraZeneca's Enhertu Shows Significant PFS Improvement As First-Line HER2 Mutant NSCLC Treatment In DESTINY-Lung04 Phase 3 Trial
Daiichi Sankyo and AstraZeneca announced that their co-developed drug, Enhertu, showed significant improvement in progression-free survival (PFS) as a first-line treatment for HER2…
Jul 31, 2026 Corporate Catalyst Bearish Impact 75
Daiichi Sankyo Co Lowers FY2026 GAAP EPS Guidance from $0.91 to $0.87 vs $1.04 Est; Raises FY2026 Sales Guidance from $14.537B to $14.684B vs $13.370B Est
Daiichi Sankyo Co. announced a reduction in its FY2026 GAAP EPS guidance from $0.91 to $0.87, which is notably below the analyst estimate of $1.04. Simultaneously, the company rais…
Jul 31, 2026 Corporate Catalyst Bullish Impact 75
EU Approves Daiichi Sankyo And AstraZeneca's Datroway For First-Line Metastatic TNBC, Showing 5.0 Month Overall Survival Improvement Over Chemotherapy In TROPION-Breast02 Trial
The EU approval of Datroway for first-line metastatic TNBC is a significant positive development for Daiichi Sankyo and AstraZeneca. This approval is based on compelling clinical t…
Jul 31, 2026 Corporate Catalyst Bearish Impact 90
Daiichi Sankyo Co Q1 EPS $0.24 Down From $0.32 YoY, Sales $3.606B Up From $3.283B YoY
Daiichi Sankyo Co (DSNKY) announced a 25% year-over-year drop in Q1 EPS, falling to $0.24 from $0.32, even as sales increased by 9.84% to $3.606 billion. This indicates a significa…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.